Halothane
|
Sevoflurane
|
|
Chemical
structure
|
Halogenated
alkane
|
Fluorinated
methyl isopropyl ether
|
Odour
|
Both
drugs have a sweet odour
|
|
Preservative
for storage
|
Yes
(thymol)
|
No
|
Blood:
gas partition coefficient
|
High
(2.4)
Slower
rate of induction and recovery
|
Lower
(0.69)
Rapid
induction and recovery
|
MAC
|
0.75
(more
potent)
|
2
(less
potent)
|
CNS
effects
|
·
Hypoxic ventilator drive is severely
depressed by halothane.
·
Blunts autoregulation and increases cerebral
blood flow.
·
Maximum increase in CBF among
currently used volatile agents
|
Causes
an increase in CBF but to a lesser extent as compared to halothane.
|
CVS
effects
|
Causes
more severe cardiac depression
·
Direct myocardial depression resulting
in dose dependent decrease in BP
·
Decreases coronary blood flow due to
fall of BP
·
Attenuates Baroreceptor reflex thus
blunting the ability to maintain cardiac output by increasing heart rate
(like an inhalational β-blocker)
·
Sensitized heart to arrythmogenic
effects of catecholamines (epinephrine).
|
More
cardiac stable
·
Comparatively less depression of
myocardial contractility
·
Mild decrease in systemic vascular
resistance at equipotent dose
·
Does not sensitize the heart to catecholamines.
|
Hepatic
effects
|
·
Decreases hepatic blood flow
·
Hepatotoxic especially on frequent
repeated exposure—halothane hepatitis
|
·
Decreases portal venous flow but,
increases hepatic artery flowà so overall, hepatic blood
flow is maintained
|
Renal
effects
|
·
Decreases renal blood flow, GFR and
urinary output
·
Reduction in renal blood flow is more
as compared to reduction in GFR resulting in an increase in filtration
fraction
|
·
Slight decrease in renal blood flow,
GFR and urine output—comparatively to a lesser degree
·
Reacts with dry barium hydroxide
(baralyme) resulting in production of Compound A—found nephrotoxic in animal
studies.
|
On
children
|
·
Less emergence reaction
·
Less nausea/vomiting postoperative
|
·
More emergence reaction
·
Comparatively more nausea/vomiting postoperative
|
Upper
limit of concomitant epinephrine use
|
1.5
mcg/kg
|
4.5mcg/kg
|
Drug
interactions
|
·
Potentiates non-depolarising
neuromuscular blockers
·
Exaggerated myocardial depression when
used with beta blockers (eg propranolol) and calcium channel blockers (eg
verapamil)
·
Increased lability of BP when used in
patients receiving tricyclic antidepressants and monoamine oxidase inhibitors
·
Increased incidence of arrhythmia when
combined with aminophylline
|
·
Potentiates non-depolarising
neuromuscular blockers
·
Otherwise, significant drug
interaction among other commonly used drugs in clinical practice
|
Malignant
hyperthermia
|
Both
drugs can trigger an attack
|
Sunday, May 31, 2015
Halothane vs Sevoflurane
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment